Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9019208 | 1.00 | TSHR (0.30) | TSHR | |
| SCHEMBL9019210 | 1.00 | TSHR (0.30) | TSHR | |
| SCHEMBL17583244 | 0.86 | TSHR (0.30) | TSHR | |
| SCHEMBL4904318 | 0.79 | TSHR (0.39) | TSHR | |
| SCHEMBL9238797 | 0.79 | TSHR (0.41) | TSHR | |
| SCHEMBL5709953 | 0.78 | LMNA (0.39) | TSHR | |
| SCHEMBL7159454 | 0.76 | TSHR (0.37) | TSHR | |
| SCHEMBL7161753 | 0.76 | TSHR (0.37) | TSHR | |
| SCHEMBL17789995 | 0.75 | ALDH1A1 (0.32) | TSHR | |
| SCHEMBL9019061 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312474-A1 | ANTHRACYCLINS AND CONJUGATES THEREOF | SYNAFFIX B.V. (NL) | 2025-10-09 | — | — | US | disclosed |
| EP-4572798-A1 | ANTHRACYCLINS AND CONJUGATES THEREOF | Synaffix B.V. (NL) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038065-A1 | ANTHRACYCLINS AND CONJUGATES THEREOF | SYNAFFIX B.V. (NL) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312474-A1 | ANTHRACYCLINS AND CONJUGATES THEREOF | ANTXR2, NCL, DUT | TSHR 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.